Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

Recently, immune checkpoint inhibitors (ICIs) therapy has become a promising therapeutic
strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects …

Tumors responding to immune checkpoint inhibitors (ICIs) have a higher level of immune
infiltrates and/or an Interferon (IFN) signature indicative of a T-cell-inflamed phenotype …

Merkel cell carcinoma (MCC) is a rare skin cancer, accounting for less than 1% of all
cutaneous malignancies. It is found predominantly in white populations and risk factors …

PURPOSE Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the
Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for …

Importance Merkel cell carcinoma (MCC) is an aggressive skin cancer that is associated
with poor survival outcomes in patients with distant metastatic disease. Results of part A of …

PURPOSE Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always
fatal and lacks effective systemic treatment options for patients with BRAF-wild type disease …

Programmed death-ligand 1 (PD-L1) is an immune checkpoint inhibitor that binds to its
receptor PD-1 expressed by T cells and other immune cells to regulate immune responses; …

PURPOSE Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven
by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed …